137 related articles for article (PubMed ID: 34508710)
1. Synthesis and biological evaluation of selected 7H-pyrrolo[2,3-d]pyrimidine derivatives as novel CDK9/CyclinT and Haspin inhibitors.
Pieterse L; Beteck RM; Baratte B; Jesumoroti OJ; Robert T; Ruchaud S; Bach S; Legoabe LJ
Chem Biol Interact; 2021 Nov; 349():109643. PubMed ID: 34508710
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of 7-azaindole derivatives bearing benzocycloalkanone motifs as protein kinase inhibitors.
Qhobosheane MA; Legoabe LJ; Josselin B; Bach S; Ruchaud S; Petzer JP; Beteck RM
Bioorg Med Chem; 2020 Jun; 28(11):115468. PubMed ID: 32284225
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of C3 substituted chalcone-based derivatives of 7-azaindole as protein kinase inhibitors.
Qhobosheane MA; Legoabe LJ; Josselin B; Bach S; Ruchaud S; Beteck RM
Chem Biol Drug Des; 2020 Dec; 96(6):1395-1407. PubMed ID: 32558155
[TBL] [Abstract][Full Text] [Related]
4. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.
Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T
Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of dinaciclib and CAN508 hybrids as CDK inhibitors.
Odeh DM; Allam HA; Baselious F; Mahmoud WR; Odeh MM; Ibrahim HS; Abdel-Aziz HA; Mohammed ER
Drug Dev Res; 2024 May; 85(3):e22193. PubMed ID: 38685605
[TBL] [Abstract][Full Text] [Related]
6. Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.
Czudor Z; Balogh M; Bánhegyi P; Boros S; Breza N; Dobos J; Fábián M; Horváth Z; Illyés E; Markó P; Sipos A; Szántai-Kis C; Szokol B; Őrfi L
Bioorg Med Chem Lett; 2018 Feb; 28(4):769-773. PubMed ID: 29329658
[TBL] [Abstract][Full Text] [Related]
7. Design of new disubstituted imidazo[1,2-
Elie J; Feizbakhsh O; Desban N; Josselin B; Baratte B; Bescond A; Duez J; Fant X; Bach S; Marie D; Place M; Ben Salah S; Chartier A; Berteina-Raboin S; Chaikuad A; Knapp S; Carles F; Bonnet P; Buron F; Routier S; Ruchaud S
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1840-1853. PubMed ID: 33040634
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors.
Hu H; Wu J; Ao M; Zhou X; Li B; Cui Z; Wu T; Wang L; Xue Y; Wu Z; Fang M
Bioorg Chem; 2020 Sep; 102():104064. PubMed ID: 32653610
[TBL] [Abstract][Full Text] [Related]
9. Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.
Shao H; Shi S; Huang S; Hole AJ; Abbas AY; Baumli S; Liu X; Lam F; Foley DW; Fischer PM; Noble M; Endicott JA; Pepper C; Wang S
J Med Chem; 2013 Feb; 56(3):640-59. PubMed ID: 23301767
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Shi X; Quan Y; Wang Y; Wang Y; Li Y
Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
[TBL] [Abstract][Full Text] [Related]
12. 3H-pyrazolo[4,3-f]quinoline haspin kinase inhibitors and anticancer properties.
Opoku-Temeng C; Dayal N; Aflaki Sooreshjani M; Sintim HO
Bioorg Chem; 2018 Aug; 78():418-426. PubMed ID: 29698892
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.
Zhang M; Jiang L; Tao J; Pan Z; He M; Su D; He G; Jiang Q
Bioorg Med Chem; 2019 Jun; 27(11):2268-2279. PubMed ID: 31014565
[TBL] [Abstract][Full Text] [Related]
14. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
Lee JH; El-Damasy AK; Seo SH; Gadhe CG; Pae AN; Jeong N; Hong SS; Keum G
Bioorg Med Chem; 2018 Nov; 26(21):5596-5611. PubMed ID: 30385226
[TBL] [Abstract][Full Text] [Related]
15. Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.
Phillipson LJ; Segal DH; Nero TL; Parker MW; Wan SS; de Silva M; Guthridge MA; Wei AH; Burns CJ
Bioorg Med Chem; 2015 Oct; 23(19):6280-96. PubMed ID: 26349627
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
Shao H; Foley DW; Huang S; Abbas AY; Lam F; Gershkovich P; Bradshaw TD; Pepper C; Fischer PM; Wang S
Eur J Med Chem; 2021 Mar; 214():113244. PubMed ID: 33581551
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors.
Xu Z; Zhang B; Liu Z; Gou S
Eur J Med Chem; 2022 Dec; 244():114875. PubMed ID: 36332552
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.
Németh G; Greff Z; Sipos A; Varga Z; Székely R; Sebestyén M; Jászay Z; Béni S; Nemes Z; Pirat JL; Volle JN; Virieux D; Gyuris Á; Kelemenics K; Ay E; Minarovits J; Szathmary S; Kéri G; Orfi L
J Med Chem; 2014 May; 57(10):3939-65. PubMed ID: 24742150
[TBL] [Abstract][Full Text] [Related]
19. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors.
Moriarty KJ; Koblish HK; Garrabrant T; Maisuria J; Khalil E; Ali F; Petrounia IP; Crysler CS; Maroney AC; Johnson DL; Galemmo RA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5778-83. PubMed ID: 16949284
[TBL] [Abstract][Full Text] [Related]
20. Computational study and peptide inhibitors design for the CDK9 - cyclin T1 complex.
Randjelović J; Erić S; Savić V
J Mol Model; 2013 Apr; 19(4):1711-25. PubMed ID: 23296566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
